Mylan Delays Restructuring Amid COVID-19

Follows Postponement Of Merger With Pfizer’s Upjohn Business

Mylan has delayed a major restructuring program ahead of its planned merger with Pfizer’s Upjohn unit due to the impact of the COVID-19 pandemic, which at the same time brought tailwinds for the firm’s first-quarter results.

Lego
Mylan is waiting to restructure its business • Source: Shutterstock

Mylan has announced a delay to a major company restructuring initiative that it had been planning ahead of its merger with Pfizer’s Upjohn mature brands and off-patent business, which is due to close by the end of this year following a coronavirus-related delay.

Revealing that the 2020 restructuring program had also been delayed “as a result of the COVID-19 pandemic and the related...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business